The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
CA184-156: A randomized, multicenter, double-blind, phase III trial comparing the efficacy of ipilimumab (Ipi) plus etoposide/platinum (EP) versus EP in subjects with newly diagnosed extensive-stage disease small cell lung cancer (ED-SCLC).
David R. Spigel
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Christoph Zielinski
Honoraria - Bristol-Myers Squibb
Sabine Maier
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Veerle de Pril
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Justin P. Fairchild
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Jean-Marie Cuillerot
Employment or Leadership Position - Bristol-Myers Squibb
Consultant or Advisory Role - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Martin Reck
Consultant or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; Pfizer; Roche
Honoraria - AstraZeneca; Daiichi Sankyo; Lilly; Pfizer; Roche